Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for GVHD Prophylaxis After HSCT
NCT04131738Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2020
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of baricitinib in graft-versus-host disease (GVHD) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Cumulative incidence of graft failure at 28 days and Cumulative incidence of grade III-IV acute GVHD at Day 100. Started Apr 2020; status: completed.
02
Drugs
baricitinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04131738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131738.